What question did this study set out to answer?

The aim was to evaluate the efficacy and tolerability of ASC30, a novel oral GLP-1 receptor agonist, in participants with obesity.

June 7, 2026

1672-P: Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity

Key Points

The aim was to evaluate the efficacy and tolerability of ASC30, a novel oral GLP-1 receptor agonist, in participants with obesity.
Conducted a 13-week, randomized, double-blind, placebo-controlled design at U.S. sites.
A total of 125 participants received either placebo or ASC30 at doses of 20, 40, or 60 mg once daily via weekly titration.
Evaluated weight loss and gastrointestinal tolerability over the study period.
ASC30 achieved placebo-adjusted weight loss of 7.7% at the 60 mg dose by Week 13.
GI adverse events were primarily grade 1 or 2 and mainly during titration, with a vomiting rate about half that of OFG.
Discontinuation rates due to adverse events were low, with only 0.0% for the 60 mg ASC30 group.

Abstract

Introduction and Objective: ASC30 is a small-molecule oral GLP-1 RA discovered by Ascletis with a similar chemical scaffold but differentiated pharmacological properties compared to orforglipron (OFG). Methods: This 13-week, randomized, double-blind, placebo-controlled, multicenter Phase II study was conducted at U.S. sites. A total of 125 participants were randomized to placebo or ASC30 oral tablet with target doses of 20, 40, or 60 mg once daily via weekly titration. Results: At Week 13, ASC30 showed dose-dependent placebo-adjusted weight reductions of 5.4%, 7.0%, and 7.7% for 20, 40 and 60 mg doses, respectively, with no plateau. Mean baseline body weight and BMI were 107.3 kg and 38.6 kg/m². ASC30 demonstrated favorable GI tolerability; all GI adverse events were grade 1 or 2 and occurred mainly during titration. Vomiting rate with ASC30 titrated weekly was about half the vomiting rate with OFG titrated weekly. Overall GI tolerability of ASC30 titrated weekly was comparable to OFG titrated every four weeks (Table 1). No grade ≥3 drug-related AEs or SAEs were reported. Treatment discontinuation rates due to AEs by dose group were 7.3% (20 mg), 7.5% (40 mg), and 0.0% (60 mg) for ASC30 oral tablet compared with 0.0% for placebo. Conclusion: ASC30 oral tablet showed dose-dependent weight loss with a favorable GI tolerability profile, supporting its potential as best-in-class oral GLP-1 RA. Disclosure J.J. Wu: None. V. Wang: None.

Mark Helpful

Bookmark

Relay